Press Release

AROG Pharmaceuticals to Present Clinical Data on Crenolanib at the 2016 American Society of Hematology Annual Meeting

Posted on: 07 Nov 16

DALLAS, Nov. 07, 2016 (GLOBE NEWSWIRE) -- AROG Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, today announced its abstract highlighting the company’s lead product candidate, crenolanib, in a combination study with cytarabine and anthracycline has been selected for an oral presentation at the 2016 American Society of Hematology (ASH) annual meeting. Crenolanib continues to demonstrate best-in-class properties in the treatment of acute myeloid leukemia (AML) with FLT3 mutations. In addition, AROG will present three posters on its combination studies of crenolanib with sorafenib, idarubicin and high-dose ara-C (HiDAC), and high-dose ara-C and mitoxantrone (HAM) in AML patients with FLT3 mutations. The ASH annual meeting will take place December 3-6, 2016 in San Diego, California. Details of the abstract presentations are provided below.

Oral Presentation, Abstract #94664

Title: Crenolanib, a type I FLT3 TKI, can be safely combined with cytarabine and anthracycline induction chemotherapy and results in high response rates in patients with newly diagnosed FLT3 mutant acute myeloid leukemia (AML)

AROG Pharmaceuticals is a private, clinical-stage biopharmaceutical company that has leveraged its platform of benzimidazole derivatives to develop a robust drug pipeline of orally available, potent, and selective small molecule type I kinase inhibitors. AROG is poised to enroll patients in pivotal, randomized Phase III trials of its lead molecule, crenolanib. In addition to the four clinical trials it has already completed, AROG is also engaged in three ongoing Phase II clinical trials. For more information, please visit the company’s website, http://www.arogpharma.com.

About Crenolanib

AROG’s lead molecule, crenolanib, is currently being clinically investigated as a treatment for multiple cancers, including acute myeloid leukemia (AML), gastrointestinal stromal tumors (GIST), glioma, and non-small cell lung cancer (NSCLC). It is an orally bioavailable benzimidazole type I kinase inhibitor that selectively and potently inhibits signaling of wild-type and mutant isoforms of class III receptor tyrosine kinases FLT3 and PDGFRα/β. This molecule has an established record of patient safety and has been used to treat over 250 patients from around the world.

About FLT3

FLT-3 is a class III receptor tyrosine kinase, and its signaling is considered important for the normal development of hematopoietic stem cells and progenitor cells. The FLT-3 gene is one of the most frequently mutated genes (~35%) in acute myeloid leukemia (AML). One such mutation, internal tandem duplications of FLT-3 (FLT3-ITD), is a prognostic indicator associated with adverse disease outcome. Also, FLT-3 (FLT3-D835), is known to be a common cause of resistance to other FLT3 inhibitors.

About PDGFRα/β

Platelet-derived growth factor receptors (PDGFR) -α and -β are cell surface tyrosine kinase receptors and are important factors regulating cell proliferation and cell development, as well as several diseases, including cancers like brain tumors and sarcomas. In clinical tests, crenolanib has been shown to inhibit both PDGFR-α and -β phosphorylation, thus preventing downstream signaling.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.